PD-L1 ≥1%
4 drugsPredictive biomarker for patient selection in 20 indications
4
Approved Drugs
20
Indications
2
Companies
PD-L1 ≥1% is a precision-medicine biomarker linked to 4 FDA-approved targeted drugs from 2 companies, spanning 20 indications including Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing PD-L1 ≥1% drugs below.
Search PD-L1 ≥1% Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PD-L1 ≥1%
| Drug | Company | Therapeutic Area |
|---|---|---|
| OPDIVO | Bristol-Myers Squibb | Oncology |
| OPDIVO QVANTIG | Bristol-Myers Squibb | Oncology |
| TECENTRIQ | Roche | Oncology |
| YERVOY | Bristol-Myers Squibb | Oncology |
PD-L1 ≥1% Indications
Non-Small Cell Lung Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Melanoma Alveolar Soft Part Sarcoma Muscle Invasive Bladder Cancer Renal Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Urothelial Carcinoma Colorectal Cancer Esophageal Cancer Gastroesophageal Junction Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Esophageal Adenocarcinoma Malignant Pleural Mesothelioma Classical Hodgkin Lymphoma Cutaneous Melanoma Microsatellite Instability-High Cancer Mismatch Repair Deficient Cancer